vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and Evolus, Inc. (EOLS). Click either name above to swap in a different company.
DYNAVAX TECHNOLOGIES CORP is the larger business by last-quarter revenue ($94.9M vs $90.3M, roughly 1.1× Evolus, Inc.). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 0.1%, a 28.2% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 14.4%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $11.3M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 23.4%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
Evolus, Inc. is a medical aesthetics company focused on developing and commercializing non-surgical cosmetic treatment solutions. Its flagship product is a prescription neuromodulator designed to reduce moderate to severe glabellar frown lines, serving licensed aesthetic healthcare providers and consumers across North America, Europe, and key Asia-Pacific regional markets.
DVAX vs EOLS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $90.3M |
| Net Profit | $26.9M | $130.0K |
| Gross Margin | — | 65.7% |
| Operating Margin | 22.4% | 4.7% |
| Net Margin | 28.4% | 0.1% |
| Revenue YoY | 17.7% | 14.4% |
| Net Profit YoY | 53.0% | 101.9% |
| EPS (diluted) | $0.21 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $90.3M | ||
| Q3 25 | $94.9M | $69.0M | ||
| Q2 25 | $95.4M | $69.4M | ||
| Q1 25 | $68.2M | $68.5M | ||
| Q4 24 | $72.0M | $78.9M | ||
| Q3 24 | $80.6M | $61.1M | ||
| Q2 24 | $73.8M | $66.9M | ||
| Q1 24 | $50.8M | $59.3M |
| Q4 25 | — | $130.0K | ||
| Q3 25 | $26.9M | $-15.7M | ||
| Q2 25 | $18.7M | $-17.1M | ||
| Q1 25 | $-96.1M | $-18.9M | ||
| Q4 24 | $7.0M | $-6.8M | ||
| Q3 24 | $17.6M | $-19.2M | ||
| Q2 24 | $11.4M | $-11.3M | ||
| Q1 24 | $-8.7M | $-13.1M |
| Q4 25 | — | 65.7% | ||
| Q3 25 | — | 66.5% | ||
| Q2 25 | — | 65.3% | ||
| Q1 25 | — | 68.1% | ||
| Q4 24 | — | 66.7% | ||
| Q3 24 | — | 68.9% | ||
| Q2 24 | — | 70.3% | ||
| Q1 24 | — | 68.3% |
| Q4 25 | — | 4.7% | ||
| Q3 25 | 22.4% | -16.7% | ||
| Q2 25 | 15.1% | -14.7% | ||
| Q1 25 | -34.7% | -22.1% | ||
| Q4 24 | -2.3% | -2.9% | ||
| Q3 24 | 12.5% | -25.3% | ||
| Q2 24 | 7.0% | -11.5% | ||
| Q1 24 | -35.0% | -15.0% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 28.4% | -22.8% | ||
| Q2 25 | 19.6% | -24.7% | ||
| Q1 25 | -141.0% | -27.6% | ||
| Q4 24 | 9.8% | -8.6% | ||
| Q3 24 | 21.8% | -31.4% | ||
| Q2 24 | 15.4% | -17.0% | ||
| Q1 24 | -17.2% | -22.1% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | $0.21 | $-0.24 | ||
| Q2 25 | $0.14 | $-0.27 | ||
| Q1 25 | $-0.77 | $-0.30 | ||
| Q4 24 | $0.07 | $-0.11 | ||
| Q3 24 | $0.12 | $-0.30 | ||
| Q2 24 | $0.08 | $-0.18 | ||
| Q1 24 | $-0.07 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $53.8M |
| Total DebtLower is stronger | — | $146.1M |
| Stockholders' EquityBook value | $534.1M | $-23.1M |
| Total Assets | $946.5M | $225.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $53.8M | ||
| Q3 25 | $160.2M | $43.5M | ||
| Q2 25 | $99.1M | $61.7M | ||
| Q1 25 | $51.7M | $67.9M | ||
| Q4 24 | $95.9M | $87.0M | ||
| Q3 24 | $119.3M | $85.0M | ||
| Q2 24 | $112.5M | $93.7M | ||
| Q1 24 | $132.0M | $97.0M |
| Q4 25 | — | $146.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $121.8M | ||
| Q4 24 | — | $121.5M | ||
| Q3 24 | — | $121.2M | ||
| Q2 24 | — | $120.9M | ||
| Q1 24 | — | $120.6M |
| Q4 25 | — | $-23.1M | ||
| Q3 25 | $534.1M | $-28.8M | ||
| Q2 25 | $494.2M | $-18.7M | ||
| Q1 25 | $530.9M | $-6.6M | ||
| Q4 24 | $596.8M | $5.5M | ||
| Q3 24 | $681.4M | $5.9M | ||
| Q2 24 | $642.8M | $19.3M | ||
| Q1 24 | $618.5M | $18.4M |
| Q4 25 | — | $225.9M | ||
| Q3 25 | $946.5M | $219.0M | ||
| Q2 25 | $918.4M | $228.8M | ||
| Q1 25 | $945.9M | $213.4M | ||
| Q4 24 | $986.3M | $232.6M | ||
| Q3 24 | $1.1B | $229.6M | ||
| Q2 24 | $1.0B | $233.8M | ||
| Q1 24 | $986.6M | $226.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 22.00× | ||
| Q3 24 | — | 20.58× | ||
| Q2 24 | — | 6.26× | ||
| Q1 24 | — | 6.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $12.8M |
| Free Cash FlowOCF − Capex | $32.6M | $11.3M |
| FCF MarginFCF / Revenue | 34.4% | 12.6% |
| Capex IntensityCapex / Revenue | 1.3% | 1.6% |
| Cash ConversionOCF / Net Profit | 1.26× | 98.67× |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $-45.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $12.8M | ||
| Q3 25 | $33.8M | $-14.7M | ||
| Q2 25 | $23.4M | $-24.8M | ||
| Q1 25 | $-19.6M | $-15.6M | ||
| Q4 24 | $53.0M | $4.8M | ||
| Q3 24 | $19.5M | $-5.7M | ||
| Q2 24 | $10.7M | $-6.5M | ||
| Q1 24 | $-16.7M | $-10.6M |
| Q4 25 | — | $11.3M | ||
| Q3 25 | $32.6M | $-15.6M | ||
| Q2 25 | $22.0M | $-25.5M | ||
| Q1 25 | $-23.6M | $-16.0M | ||
| Q4 24 | $49.5M | $4.4M | ||
| Q3 24 | $18.1M | $-6.0M | ||
| Q2 24 | $9.9M | $-6.9M | ||
| Q1 24 | $-17.4M | $-10.9M |
| Q4 25 | — | 12.6% | ||
| Q3 25 | 34.4% | -22.7% | ||
| Q2 25 | 23.0% | -36.7% | ||
| Q1 25 | -34.6% | -23.3% | ||
| Q4 24 | 68.8% | 5.5% | ||
| Q3 24 | 22.5% | -9.9% | ||
| Q2 24 | 13.5% | -10.4% | ||
| Q1 24 | -34.3% | -18.3% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | 1.3% | 1.4% | ||
| Q2 25 | 1.5% | 1.0% | ||
| Q1 25 | 5.8% | 0.5% | ||
| Q4 24 | 4.8% | 0.6% | ||
| Q3 24 | 1.7% | 0.5% | ||
| Q2 24 | 1.1% | 0.7% | ||
| Q1 24 | 1.5% | 0.4% |
| Q4 25 | — | 98.67× | ||
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
EOLS
Segment breakdown not available.
